Optimal radiotherapy dose in cervical esophageal squamous cell carcinoma patients treated with definitive concurrent chemoradiotherapy: A population based study

<jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>The optimal radiotherapy dose for locally advanced cervical esophageal squamous cell carcinoma (C‐ESqCC) treated with definitive concurrent chemoradiotherapy (dCCRT) is unclear. Here, we aimed to compare the survival of those treated with high dose versus standard dose via a population based approach.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Eligible C‐ESqCC patients diagnosed between 2011 and 2017 were identified via the Taiwan Cancer Registry. We used propensity score (PS) weighting to balance observable potential confounders between groups. The hazard ratio (HR) of death and incidence of esophageal cancer mortality (IECM) were compared between high (60–70 Gy) and standard dose (50–50.4 Gy). We also evaluated the outcome in supplementary analyses via alternative approaches.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Our primary analysis consisted of 141 patients in whom covariates were well balanced after PS weighting. The HR of death when high dose was compared with standard dose was 0.65 (95% confidence interval [CI]: 0.4–1.03, <jats:italic>p</jats:italic> = 0.07). The HR of IECM was 0.74 (<jats:italic>p</jats:italic> = 0.45). The HR of OS remained similarly insignificant in supplementary analyses.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>We observed a trend in favor of high radiotherapy dose versus standard dose for C‐ESqCC treated with dCCRT in this population‐based nonrandomized study. Further studies are needed to confirm the findings of the study.</jats:p></jats:sec>